Table 3.
Treatment Exposure and Dose Modifications
| N = 12 | |||||
|---|---|---|---|---|---|
| Parameter | Bevacizumab | nab-Paclitaxel | Leucovorin | Oxaliplatin | 5-Fluorouracil |
| Treatment exposure | |||||
| Treatment duration, median (range), weeks | 27.85 (3.7–51.4) | 27.00 (3.7–51.4) | 27.85 (3.7–51.4) | 22.00 (3.7–51.4) | 28.00 (3.9–53.6) |
| Treatment cycles, median (range), n | 7.0 (1–13) | 7.0 (1–13) | 7.0 (1–13) | 5.5 (1–13) | 7.0 (1–13) |
| Relative dose intensity, median, % | 94.02 | 88.25 | 93.64 | 88.41 | 84.35 |
| Cumulative dose, median (range), mg | 4685.50 (500.0–8217.0) | 1343.63 (222.0–2737.9) | 413.87 (57.9–728.9) | 573.73 (115.8–1462.2) | 14,253.36 (2161.6–25,630.9) |
| Dose modifications | |||||
| Patients with ≥1 dose reduction, n (%) | 0 | 5 (41.7) | 0 | 6 (50.0) | 7 (58.3) |
| Patients with ≥1 dose delay, n (%) | 5 (41.7) | 5 (41.7) | 5 (41.7) | 5 (41.7) | 5 (41.7) |